Status:
COMPLETED
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
Lead Sponsor:
Eli Lilly and Company
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
Eligibility Criteria
Inclusion
- 18-65 years old
- Diagnosed with Schizophrenia or Schizoaffective disorder
- Ability to visit the doctor's office for scheduled visits
Exclusion
- Women who are pregnant or breastfeeding
- Have a body mass index (BMI) greater than 40
- Have diabetes, heart disease or any other unstable illness
- Have known positive human immunodeficiency virus (HIV)
- Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00190749
Start Date
October 1 2003
End Date
June 1 2008
Last Update
May 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States, 92161